Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview
In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying advanced immunology in the fight against both solid and hematologic malignancies. By leveraging its robust DeltEx platform, In8Bio is pioneering the integration of cell-based therapies into standard clinical protocols, a subject of high relevance in the fields of oncology and immunotherapy.
Clinical Programs and Technological Innovation
The company is deeply engaged in multiple clinical programs that advance its gamma-delta T cell product candidates into various stages of clinical investigation. Its innovative approach harnesses the unique ability of gamma-delta T cells to recognize and destroy cancer cells while differentiating between healthy and diseased tissues. The immunotherapies developed by In8Bio are designed to overcome current challenges in cancer treatment by demonstrating resilience in the presence of conventional modalities such as chemotherapy. This novel methodology indicates a significant step forward in addressing persistent gaps in progression-free survival for patients afflicted with difficult-to-treat cancers.
Pipeline and Portfolio
In8Bio maintains a diverse portfolio of cell therapy candidates that target both solid tumors, such as aggressive brain cancers, and liquid tumors, including high-risk hematologic malignancies. The company emphasizes the potential of its genetically modified gamma-delta T cells which are engineered to be chemotherapy-resistant, thereby enabling their effective use in combination with standard-of-care treatments. Its strategic portfolio reflects a deliberate focus on creating therapies that provide robust antitumor activity with a favorable safety profile, which is crucial in clinical settings.
Market Position and Competitive Landscape
Operating within a competitive and dynamic segment of the biotechnology and oncology markets, In8Bio distinguishes itself by being one of the first companies to translate genetically modified gamma-delta T cell therapy into clinical studies. The company’s efforts to integrate advanced cell therapy with conventional cancer management protocols underscore its role as a pioneer in the immunotherapy space. Its scientific and clinical strategies are rooted in extensive research, aiming to expand treatment options for patients with unmet medical needs while setting a benchmark for future research in cell-based therapies.
Research and Development Focus
The core of In8Bio’s business model lies in its commitment to rigorous research and clinical validation. The company employs a systematic approach to clinical investigation, ensuring that its product candidates are evaluated through well-designed studies. This commitment to science and robust clinical trial methodologies not only enhances the credibility of its findings but also contributes to the broader scientific understanding of gamma-delta T cell functions in oncology. The integration of innovative technologies with traditional treatment regimens speaks to the company’s strategy of enhancing therapeutic durability and safety.
Operational Excellence and Strategic Vision
In8Bio is characterized by its deep commitment to scientific excellence and operational transparency. Its research pipeline is supported by meticulous clinical studies that investigate both short-term efficacy and long-term safety profiles of its cell therapies. By positioning its programs at the interface of immunology and oncology, the company provides a pertinent example of how novel biotechnology can offer alternative options for cancer patients. This blend of advanced immunotherapeutic strategies and rigorous clinical science reinforces In8Bio’s reputation as a credible and knowledgeable entity in the biopharmaceutical landscape.
Investor Insights and Frequently Asked Questions
Investors and industry researchers looking into In8Bio will find that the company’s emphasis on gamma-delta T cell therapies offers a unique intersection of cellular immunotherapy and targeted cancer treatments. The detailed clinical programs, alongside strategic R&D initiatives, provide ample context on the company’s approach to addressing unmet needs in oncology. By maintaining a balanced perspective on both the promise and challenges inherent in advanced cell therapies, In8Bio continues to contribute to the evolution of cancer treatment paradigms with ongoing scientific rigor and clinical evaluation.
IN8bio (NASDAQ: INAB) has announced it will present new preclinical data on its novel gamma-delta (γδ) T cell engager platform at the AACR Annual Meeting 2025 in Chicago. The presentation will showcase the company's innovative approach to cancer immunotherapy, combining gamma-delta T cells' innate tumor-recognition capabilities with bispecific engagers.
The research focuses on overcoming limitations of current CD-3 based engager therapies by leveraging unique properties of gamma-delta T cells, including tissue residence, phagocytosis, and low IL-6 secretion. Early findings in AML and B-ALL demonstrate potential for targeted immune responses against multiple antigens.
The poster presentation titled 'A novel gamma-delta T cell engager platform for cancer immunotherapy' (Abstract #7321) will be presented on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.
William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:
- Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
- Chairing the 'State of the IO Market, Investments and Deals Plenary'
- Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT
The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.
IN8bio (INAB) reported its Q4 and full-year 2024 financial results, highlighting significant clinical progress in its gamma-delta T cell therapies. The company's INB-100 program demonstrated 100% long-term durable response rates in high-risk AML patients as of January 2025. The Phase 1 INB-200 trial for glioblastoma showed promising durability, with five patients remaining alive and one patient progression-free for 40.5 months.
Financial highlights include R&D expenses of $17.2M for 2024 (vs $16.8M in 2023), G&A expenses of $12.6M (vs $13.5M), and a net loss of $30.7M ($0.57 per share). The company ended 2024 with cash of $11.1M, raised additional $4.1M in February 2025, and expects runway into March 2026.
IN8bio introduced its INB-600 platform featuring a novel gamma-delta T Cell engager targeting CD19 for oncology and autoimmune diseases. The company implemented cost-saving measures and paused the Phase 2 INB-400 glioblastoma program to optimize resource allocation.
IN8bio (NASDAQ: INAB) has unveiled INB-600, a novel gamma-delta (γδ) T cell-based TCE platform designed to overcome the limitations of current γδ TCEs. The platform's first candidate, INB-619, targets CD19 for applications in leukemias, lymphomas, and autoimmune diseases.
Key preclinical findings for INB-619 include:
- Rapid B-cell depletion with γδ T cells expanding up to 450-fold
- Simultaneous activation of both Vδ1+ and Vδ2+ T cell subsets
- Lower IL-6 secretion, potentially reducing risks of cytokine release syndrome (CRS) and neurotoxicity (ICANs)
The platform represents the first known approach capable of sustained γδ T cell expansion, offering potentially greater safety and tolerability compared to current CAR-T and TCE approaches. IN8bio plans to evaluate INB-619 in preclinical studies and seek partners for future IND-enabling trials.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. William Ho, CEO and co-founder, will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.
Interested parties can access both the live webcast and replay of the presentation through the 'Events and Presentations' section within the News & Presentations area on IN8bio's investor relations website at https://investors.in8bio.com.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's CEO and co-founder, William Ho, will deliver a presentation on Tuesday, February 25, 2025, at 11:00 a.m. ET.
The presentation will be accessible through a live webcast, with a replay option available afterward. Interested parties can access the webcast through the provided link or find it in the 'Events and Presentations' section under News & Presentations on IN8bio's investor relations website.
IN8bio (Nasdaq: INAB) presented Phase 1 data for INB-100, its allogeneic gamma-delta T cell therapy, showing significant promise in treating high-risk acute myeloid leukemia (AML). The data revealed zero relapses in AML patients with a median follow-up of 20.1 months. The therapy demonstrated impressive outcomes with a 90.9% progression-free survival rate and 100% overall survival at one year.
The treatment showed a favorable safety profile with no cytokine release syndrome, neurotoxicity, or dose-limiting toxicities. Evidence of in vivo expansion and long-term persistence of gamma-delta T cells was observed. With approximately 20,000 new AML cases and 11,500 deaths annually in the U.S., and post-HSCT relapse occurring in up to 50% of patients, INB-100 addresses a significant unmet medical need.
The company plans to complete enrollment of the expansion cohort in 2025, with FDA confirming relapse-free survival as an acceptable primary endpoint for a future pivotal trial.
IN8bio (NASDAQ: INAB) reported updated results from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for acute myeloid leukemia (AML) patients. 100% of AML patients remain in complete remission with a median follow-up of 20.1 months, with the original cohort reaching a median CR of 23.3 months. Several patients have maintained remission for over three years.
The trial demonstrated significantly higher survival rates compared to historical data, with 90.9% progression-free survival (PFS) and 100% overall survival (OS) at one year across all patients. For AML patients specifically, both PFS and OS were 100% at one year. The therapy shows particular promise in older, high-risk patients receiving reduced intensity conditioning, with a median age of 68. Notably, the treatment has been well-tolerated with no cytokine release syndrome or neurotoxicity, and manageable graft-versus-host disease.
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in Biotech Showcase 2025 in San Francisco. CEO and co-founder William Ho will participate in two key events:
1. A panel discussion on 'The Battle Against Cancer: The Armamentarium Keeps Expanding' on Monday, January 13, 2025, at 8:00 AM PT
2. A corporate presentation on Tuesday, January 14, 2025, at 2:00 PM PT
Both events will take place at the Hilton San Francisco Union Square Hotel. The company's management will also be available for investor meetings from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference. A live webcast of the presentation will be available, and interested parties can register for the event through the provided links.
IN8bio reported updated data from its Phase 1 trial of INB-100, an allogeneic gamma-delta T cell therapy for leukemia patients. Key highlights include:
- All patients (n=10) maintained complete remission (CR) with no relapses after a median follow-up of 19.7 months
- Three high-risk cytogenetic AML patients remained in CR for over three years without maintenance therapy
- The therapy showed durable in vivo expansion and persistence of allogeneic gamma-delta T cells for 365 days post-administration
- Safety profile remained favorable with no cytokine release syndrome or neurotoxicity
The trial enrolled patients with median age 68 years, mostly diagnosed with AML in CR1. Based on positive results, the trial has been expanded with additional patient enrollment at Dose Level 2, with new data expected in H1 2025.